|
|
Discussion on Very Interesting Article
|
| Author |
Message |
Member:
scooter
|
Posted on Thursday, Nov 4, 2010 - 7:46 pm:
Interesting article for those of us that battle laminitis
https://www.thehorse.com/ViewArticle.aspx?ID=17195
|
Member:
frances
|
Posted on Friday, Nov 5, 2010 - 1:16 am:
Wow, that's a new slant. Interesting indeed. Thanks Diane.
|
Member:
ajudson1
|
Posted on Friday, Nov 5, 2010 - 7:32 am:
DrO,
I don't know if you read links that we post so I copied part of the article here and was wondering if you could comment on what kind of preventive treatment could possibly work?
"We've got a triple threat here," said Textor. "We've got our platelets activating early, probably the very first response. We've got the neutrophils (a type of white blood cell) getting activated. They start interacting with the endothelium (lining of blood vessels) and start to go across it (into the laminae). After that time, laminar breakdown begins."
Knowing this sequence of events might allow veterinarians to develop potential therapeutic strategies. Speaking generally about approaches to prevention, Textor said, "We could prevent these cells from ever getting (to the laminae) or ever being activated. We could block the things that they deliver--we could prevent the vasoconstrictors from doing their thing. Lastly, maybe we could enhance the protective mechanisms that tissue might already have in place."
Great article Diane, thanks.
|
Moderator:
DrO
|
Posted on Sunday, Nov 7, 2010 - 6:06 pm:
Angie, platelet activation in the early stages of founder was first reported in 1981 and mentioned in our article on founder under the "What Exactly is Founder" heading. The inflammatory cascade quoted was reported much even earlier and dealt with in greater detail detail in that same section. We mention platelets only briefly in the article because though experimental pretreatment with platelet inactivators prior to induction of founder was shown to be helpful for preventing founder, treatment of clinical cases primarily aspirin, even when given very early in the course, have been disappointing.
The already present primary treatment for founder, NSAID's, are exactly directed at the antiinflammatory cascade, one of which is PMN migration. It should be noted neither flunixin or bute inhibit platelet aggregation however. The summary quote from the article is certainly right on: we do not have optimal treatments for acute laminitis yet. The search for better treatment options has been a centuries long pursuit.
DrO
|
Member:
ajudson1
|
Posted on Monday, Nov 8, 2010 - 6:53 am:
Thank You DrO.
And thank you Diane for bringing the article to our attention.
|
|
|
